New heart drug AZD0233 begins first safety tests in healthy volunteers
NCT ID NCT06381466
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tested the safety of a new drug called AZD0233 in 84 healthy adults aged 18 to 50. The drug is being developed for dilated cardiomyopathy, a condition where the heart becomes enlarged and weak. Participants received either the drug or a placebo, and researchers monitored for side effects and how the drug moves through the body. The study was terminated, so its full results are not available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AZD0233
What this could lead to
If this early trial shows AZD0233 is safe, it could lead to further studies testing whether it helps control dilated cardiomyopathy.
What could go wrong
This is a very early Phase 1 trial in healthy people, not patients. The study was terminated, so results may be incomplete. Many early drugs never advance.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DILATED CARDIOMYOPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Glendale, California, 91206, United States